Resveratrol induces acute endothelium-dependent renal vasodilation mediated through nitric oxide and reactive oxygen species scavenging

American Journal of Physiology - Renal Physiology

Volumn 306, Issue 5, 2014, Pages

  Gordish, Kevin L ^a   Beierwaltes, William H ^a,b  

^a HENRY FORD HOSPITAL   (United States)

^b WAYNE STATE UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

Nitric oxide; Prostaglandins; Reactive oxygen species; Renal hemodynamics; Resveratrol; Tempol

Indexed keywords

ANGIOTENSIN 1 RECEPTOR; INDOMETACIN; N(G) NITROARGININE METHYL ESTER; NITRIC OXIDE; REACTIVE OXYGEN METABOLITE; RESVERATROL; TEMPOL; PROSTAGLANDIN; STILBENE DERIVATIVE;

ANIMAL EXPERIMENT; ARTICLE; BLOOD PRESSURE REGULATION; CONTROLLED STUDY; DOSE RESPONSE; DRUG DOSE COMPARISON; DRUG MECHANISM; KIDNEY BLOOD FLOW; KIDNEY BLOOD VESSEL; KIDNEY MASS; KIDNEY VASCULAR RESISTANCE; MALE; NONHUMAN; PRIORITY JOURNAL; RAT; VASCULAR ENDOTHELIUM; VASODILATATION; ACUTE DISEASE; ANIMAL; DISEASE MODEL; DRUG EFFECT; KIDNEY; KIDNEY CIRCULATION; METABOLISM; PHYSIOLOGY; SPRAGUE DAWLEY RAT; VASCULAR RESISTANCE; VASCULARIZATION;

NITRIC OXIDE; PROSTAGLANDINS; REACTIVE OXYGEN SPECIES; RENAL HEMODYNAMICS; RESVERATROL; TEMPOL;

ACUTE DISEASE; ANIMALS; DISEASE MODELS, ANIMAL; KIDNEY; MALE; NITRIC OXIDE; RATS; RATS, SPRAGUE-DAWLEY; REACTIVE OXYGEN SPECIES; RENAL CIRCULATION; STILBENES; VASCULAR RESISTANCE; VASODILATION;

EID: 84899138870     PISSN: 1931857X     EISSN: 15221466     Source Type: Journal    
DOI: 10.1152/ajprenal.00437.2013     Document Type: Article

References (57)

1. Araujo M, Wilcox C. Oxidative stress in hypertension: role of the kidney. Antioxid Redox Signal 20: 74-101,2013
2. Baur JA, Sinclair DA. Therapeutic potential of resveratrol: the in vivo evidence. Nat Rev Drug Discov 6: 493-506, 2006
3. Baylis C, Harton P, Engels K. Endothelium derived relaxing factor controls renal hemodynamics in normal rat kidney. J Am Soc Nephrol 6: 875-881,1990
4. Beierwaltes WH, Sigmon DH, Carretero OA. Endothelium modulates renal blood flow but not autoregulation. Am J Physiol Renal Fluid Electrolyte Physiol 262: F943-F949, 1992
5. Beierwaltes WH. Cyclooxygenase-2 products compensate for inhibition of nitric oxide regulation of renal perfusion. Am J Physiol Renal Physiol 283: F68-F72, 2002
6. Breyer MD, Breyer RM. G protein-coupled prostanoids receptors and the kidney. Annu Rev Physiol 63: 579-605, 2001
7. Bhatt JK, Thomas S, Nanjan MJ. Resveratrol supplementation improves glycemic control in type 2 diabetes mellitus. Nutr Res 32: 537-541, 2012
8. Bhatt SR, Lokhandwala MF, Banday AA. Resveratrol prevents endothelial nitric oxide synthase uncoupling and attenuates development of hypertension in spontaneously hypertensive rats. Eur J Pharmacol 30: 258-264, 2011
9. Boocock DJ, Faust GE, Patel KR, Schinas AM, Brown VA, Ducharme MP, Booth TD, Crowell JA, Perloff M, Gescher AJ, Steward WP, Brenner DE. Phase I dose escalation pharmacokinetic study in healthy volunteers of resveratrol, a potential cancer chemopreventive agent. Cancer Epidemiol Biomarkers Prev 16: 1246-1252, 2007
10. Botden IP, Oeseburg H, Durik M, Leijten FP, Van Vark-Van Der Zee LC, Musterd-Bhaggoe UM, Garrelds IM, Seynhaeve AL, Langendonk JG, Sijbrands EJ, Danser AH, Roks AJ. Red wine extract protects against oxidative-stress-induced endothelial senescence. Clin Sci (Lond) 123: 499-507, 2012
11. Burkitt MJ, Duncan J. Effects of trans-resveratrol on copper-dependent hydroxyl-radical formation and DNA damage: evidence for hydroxylradical scavenging and a novel, glutathione-sparing mechanism of action. Arch Biochem Biophys 381: 253-263, 2000
12. Chen CK, Pace-Asciak CR Vasorelaxing activity of resveratrol and quercetin in isolated rat aorta. Gen Pharmacol 27: 363-366, 1996
13. Corduneanu O, Patricia Janeiro P, Brett AM. On the electrochemical oxidation of resveratrol. Electroanalysis 18: 757-762, 2006
14. Dalaklioglu S, Ozbey G. The potent relaxant effect of resveratrol in rat corpus cavernosum and its underlying mechanisms. Int J Impot Res 25: 188-193, 2013
15. El-Mowafy AM. Resveratrol activates membrane-bound guanylyl cyclase in coronary arterial smooth muscle: a novel signaling mechanism in support of coronary protection. Biochem Biophys Res Commun 15: 1218-1224, 2012
16. Forbes JM, Coughlan MT, Cooper ME. Oxidative stress as a major culprit in kidney disease in diabetes. Diabetes 57: 1446-1454, 2008
17. Gandhi SK, Ryder DH, Brown NJ. Losartan blocks aldosterone and renal vascular responses to angiotensin II in humans. Hypertension 28: 961-966, 1996
18. Gojkovic-Bukarica L, Kanjuh V, Novakovic R, Protic D, Cvejic J, Atanackovic M. The differential effect of resveratrol on the renal artery of normal and diabetic rats. BMC Pharmacol Toxicol 13, Suppl 1: A48, 2012
19. Haque MZ, Majid DS. Assessment of renal functional phenotype in mice lacking gp91PHOX subunit of NAD(P)H oxidase. Hypertension 43: 335-340, 2004
20. Harding P, Carretero OA, Beierwaltes WH. Chronic cyclooxygenase-2 inhibition blunts low sodium-stimulated renin without changing renal haemodynamics. J Hypertens 18: 1107-1113, 2000
21. Hata AN, Breyer RM. Pharmacology and signaling of prostaglandin receptors: multiple roles in inflammation and immune modulation. Pharmacol Ther 103: 147-166, 2004
22. Hosoda R, Kuno A, Hori YS, Ohtani K, Wakamiya N, Oohiro A, Hamada H, Horio Y. Differential cell-protective function of two resveratrol (trans-3,5,4=-trihydroxystilbene) glycosides against oxidative stress. J Pharmacol Exp Ther 344: 124-132, 2013
23. Jackson EK, Heidemann HT, Branch RA, Gerkens JF. Low dose intrarenal infusion of PGE2, PGI2, and 6-keto-PGE1 vasodilate the in vivo rat kidney. Circ Res 51: 67-72, 1982
24. Johnson JL, Maddipati KR. Paradoxical effects of resveratrol on the two prostaglandin synthases. Prostaglandins Other Lipid Mediat 56: 131-143, 1998
25. Just A, Whitten C, Arendshorst W. Reactive oxygen species participate in acute renal vasoconstrictor responses induced by ETA and ETB receptors. Am J Physiol Renal Physiol 294: F719-F728, 2008
26. Kalinowski MD, Dobrucki LW, Brovkovych MS, Malinski V, Tadeusz M. Increased nitric oxide bioavailability in endothelial cells contributes to the pleiotropic effect. Circulation 105: 933-938, 2002
27. Karlssol J, Emgrad M, Burkitt MJ. Trans-resveratrol protects embryonic mesencephalic cells from tert-butyl hydroperoxide: electron paramagnetic resonance spin trapping evidence for a radical scavenging mechanism. J Neurochem 75: 141-150, 2000
28. Kopkan L, Castillo A, Navar L, Majid D. Enhanced superoxide generation modulates renal function in ANG II-induced hypertensive rats. Am J Physiol Renal Physiol 290: F80-F86, 2006
29. Lai EY, Wellstein A, Welch WJ, Wilcox CS. Superoxide modulates myogenic contractions of mouse afferent arterioles. Hypertension 58: 650-656, 2011
30. Lamas S, Rodriguez-Puyol D. Endothelium and the kidney endothelial control of vasomotor tone: the kidney perspective. Semin Nephrol 32: 156-166, 2012
31. Leonard SS, Xia C, Jiang BH, Stinefelt B, Klandorf H, Harris GK, Shi X. Resveratrol scavenges reactive oxygen species and effects radicalinduced cellular responses. Biochem Biophys Res Commun 309: 1017-1026, 2003
32. Li HF, Tian ZF, Qui XQ, Wu JX, Zhang P, Jia ZJ. A study of mechanisms involved in vasodilation induced by resveratrol in isolated porcine coronary artery. Physiol Res 55: 365-372, 2006
33. Lopez B, Salom MG, Arregui B, Valero F, Fenoy FJ. Role of superoxide in modulating the renal effects of angiotensin II. Hypertension 42: 1150-1156, 2003
34. Majid DS, Nishiyama A. Nitric oxide blockade enhances renal responses to superoxide dismutase inhibition in dogs. Hypertension 39: 293-297, 2002
35. Martinez J, Moreno JJ. Effect of resveratrol, a natural polyphenolic compound, on reactive oxygen species and prostaglandin production. Biochem Pharmacol 59: 865-870, 2000
36. Moreno JJ. Resveratrol modulates arachidonic acid release, prostaglandin synthesis, and 3T6 fibroblast growth. J Pharmacol Exp Ther 294: 333-338, 2000
37. Netherton SJ, Maurice DH. Vascular endothelial cell cyclic nucleotide phosphodiesterases and regulated cell migration: implications in angiogenesis. Mol Pharmacol 67: 263-272, 2005
38. Palmer RM, Ashton DS, Moncada Palmer S. Vascular endothelial cells synthesize nitric oxide from L-arginine. Nature 333: 664-666, 1988
39. Park SJ, Ahmad F, Philp A, Baar K, Williams T, Luo H, Ke H, Rehmann H, Taussig R, Brown AL, Kim MK, Beaven MA, Burgin AB, Manganiello V, Chung JH. Resveratrol ameliorates aging-related metabolic phenotypes by inhibiting cAMP phosphodiesterases. Cell 148: 421-433, 2012
40. Ren Y, D'Ambrosio MA, Liu R, Pagano PJ, Garvin JL, Carretero OA. Enhanced myogenic response in the afferent arteriole of spontaneously hypertensive rats. Am J Physiol Heart Circ Physiol 298: H1769-H1775, 2010
41. Rodrigo R, Gil D, Miranda-Merchak A, Kalantzidis G. Antihypertensive role of polyphenols. Adv Clin Chem 58: 225-254, 2012
42. Rodrigo R, Miranda A, Vergara L. Modulation of endogenous antioxidant system by wine polyphenols in human disease. Clin Chim Acta 412: 410-424, 2011
43. Schnackenberg CG, Welch WJ, Wilcox CS. Normalization of blood pressure and renal vascular resistance in SHR with a membrane-permeable superoxide dismutase mimetic: role of nitric oxide. Hypertension 32: 59-64, 1998
44. Sigmon DH, Beierwaltes WH. Angiotensin II: nitric oxide interaction and the distribution of blood flow. Am J Physiol Regul Integr Comp Physiol 265: R1276-R1283, 1993
45. Sigmon DH, Beierwaltes WH. Renal nitric oxide and angiotensin II interaction in renovascular hypertension. Hypertension 22: 237-242, 1993
46. Spaak J, Merlocco AC, Soleas GJ, Tomlinson G, Morris BL, Picton P, Notarius CF, Chan CT, Floras JS. Dose-related effects of red wine and alcohol on hemodynamics, sympathetic nerve activity, and arterial diameter. Am J Physiol Heart Circ Physiol 294: H605-H612, 2008
47. Spanier G, Xu H, Xia N, Tobias S, Deng S, Wojnowski L, Forstermann U, Li H. Resveratrol reduces endothelial oxidative stress by modulating the gene expression of superoxide dismutase 1 (SOD1), glutathione peroxidase 1 (GPx1) and NADPH oxidase subunit (Nox4). J Physiol Pharmacol 60, Suppl 4:111-116, 2009
48. Subramanian M, Balasubramanian P, Garver H, Northcott C, Zhao H, Haywood JR, Fink GD, MohanKumar SM, MohanKumar PS. Chronic estradiol-17 β exposure increases superoxide production in the rostral ventrolateral medulla and causes hypertension: reversal by resveratrol. Am J Physiol Regul Integr Comp Physiol 300: R1560-R1666, 2011
49. Szewczuk LM, Forti L, Stivala LA, Penning TM. Resveratrol is a peroxidase-mediated inactivator of COX-1 but not COX-2; a mechanistic approach to the design of COX-1 selective agents. J Biol Chem 279: 22727-22737, 2004
50. Tanahashi M, Hara S, Yoshida M, Suzuki-Kusaba M, Hisa H, Satoh S. Effects of rolipram and cilostamide on renal functions and cyclic AMP release in anesthetized dogs. J Pharmacol Exp Ther 289: 1533-158, 1999
51. Thandapilly SJ, LeMaistre JL, Louis XL, Anderson CM, Netticadan T, Anderson HD. Vascular and cardiac effects of grape powder in the spontaneously hypertensive rat. Am J Hypertens 25: 1070-1076, 2012
52. Tousoulis D, Kampoli AM, Tentolouris C, Papageorgiou N, Stefanadis C. The role of nitric oxide on endothelial function. Curr Vasc Pharmacol 10: 4-18, 2012
53. Walle T. Bioavailability of resveratrol. Ann NY Acad Sci 1215: 9-15, 2011
54. Wallerath T, Deckert G, Ternes T, Anderson H, Li H, Witte K, Förstermann U. Resveratrol, a polyphenolic phytoalexin present in red wine, enhances expression and activity of endothelial nitric oxide synthase. Circulation 106: 1652-1658, 2002
55. Wallerath T, Poleo D, Li H, Förstermann U. Red wine increases the expression of human endothelial nitric oxide synthase: a mechanism that may contribute to its beneficial cardiovascular effects. J Am Coll Cardiol 4: 471-478, 2003
56. Wu CC, Wu CI, Wang WY, Wu YC. Low concentrations of resveratrol potentiate the antiplatelet effect of prostaglandins. Planta Med 73: 439-443, 2007
57. Zykova TA, Zhu F, Zhai X, Ma WY, Ermakova SP, Lee KW, Bode AM, Dong Z. Resveratrol directly targets COX-2 to inhibit carcinogenesis. Mol Carcinog 47: 797-805, 2008.